Reexamining the “brain drain” effect: A replication of Ward et al. (2017)

The present study was a pre-registered direct replication of Ward et al.\u27s (2017) second experiment (OSF pre-registration found at: https://osf.io/5fq4r). This replication assigned both smartphone location (on desk, in pocket/bag, or outside of the testing room) and smartphone power (on, or off) for a total of six conditions. Participants completed an automated operation span (OSpan) task, a Cue-Dependent Go/No-Go task, and the smartphone attachment and dependency inventory. It was hypothesized that performance on an attention-demanding task (i.e., the OSpan task) would be worse for those in closer proximity to their smartphone (on desk) and that those with greater smartphone attachment and dependency would have a larger “brain drain” effect. Using the same tasks and conditions as in Ward et al.\u27s (2017) second experiment, the present study found that the “brain drain” effect did not replicate: there was no difference between smartphone location conditions on performance on either the o-span task or the go/no-go task. These findings demonstrate that the mere presence of one\u27s smartphone may not be enough to affect cognitive performance. Understanding these effects is crucial in a time where smartphones are a basic necessity

Should it Stay or Should it Go? Smartphone Dependency

As smartphones grow in use and popularity, it is important to understand the possible effects that varying levels of smartphone use may have on human cognition. Although smartphones provide many advantages for daily activities, one must also recognize the potential disadvantages. For example, smartphone use may lead to nomophobia, which is defined as the modern fear of not being able to access your smartphone or the internet (Yildirim & Correia, 2015). The present study used a pilot and main study to examine the effects smartphones have on human cognition. The pilot study was conducted to measure nomophobia, mobile phone involvement, smartphone attachment and dependency, and general smartphone use. This portion was also used to determine the paradigm for the main study. Participants in the main study completed the 12 Cambridge Brain Science tasks, which measured different aspects of

Relación entre capacitación y productividad en los trabajadores del área comercial de la empresa Idecap - Trujillo 2022

El presente trabajo de investigación tiene como objetivo determinar la relación de la capacitación y la productividad en los trabajadores del área comercial de la empresa IDECAP Trujillo 2022, con la finalidad de concientizar e informar que la capacitación al personal es importante y fundamental en toda empresa para generar productividad, sobre todo si desean alcanzar metas y objetivos y tener personal con sentido de pertenencia y permanencia. El estudio fue de tipo cuantitativo, transversal, prospectivo, de diseño no experimental-correlacional, con nivel relacional; la muestra estuvo conformada por 21 colaboradores del área comercial que laboran en la empresa IDECAP en la ciudad de Trujillo, fueron encuestados de manera libre y cumpliendo los protocolos de seguridad. Los resultados fueron que el 71,4% (15) de los trabajadores percibieron un nivel de capacitación bueno, el 85,7% (18) de los trabajadores del percibieron un nivel de productividad bueno, se obtuvo un coeficiente de correlación de Spearman de 0,714, lo que indica que se trata de una correlación positiva o directa fuerte, así como un nivel de significancia (p = 0,000) menor que 0,01. Concluyéndose que existe una relación altamente significativa entre la capacitación y la productividad en los trabajadores del área comercial en la Empresa IDECAP-Trujillo 2022

The Chandra Multi-Wavelength Project: Optical Spectroscopy and the Broadband Spectral Energy Distributions of X-ray Selected AGN

From optical spectroscopy of X-ray sources observed as part of ChaMP, we present redshifts and classifications for a total of 1569 Chandra sources from our targeted spectroscopic follow up using the FLWO, SAAO, WIYN, CTIO, KPNO, Magellan, MMT and Gemini telescopes, and from archival SDSS spectroscopy. We classify the optical counterparts as 50% BLAGN, 16% NELG, 14% ALG, and 20% stars. We detect QSOs out to z~5.5 and galaxies out to z~3. We have compiled extensive photometry from X-ray to radio bands. Together with our spectroscopic information, this enables us to derive detailed SEDs for our extragalactic sources. We fit a variety of templates to determine bolometric luminosities, and to constrain AGN and starburst components where both are present. While ~58% of X-ray Seyferts require a starburst event to fit observed photometry only 26% of the X-ray QSO population appear to have some kind of star formation contribution. This is significantly lower than for the Seyferts, especially if we take into account torus contamination at z>1 where the majority of our X-ray QSOs lie. In addition, we observe a rapid drop of the percentage of starburst contribution as X-ray luminosity increases. This is consistent with the quenching of star formation by powerful QSOs, as predicted by the merger model, or with a time lag between the peak of star formation and QSO activity. We have tested the hypothesis that there should be a strong connection between X-ray obscuration and star-formation but we do not find any association between X-ray column density and star formation rate both in the general population or the star-forming X-ray Seyferts. Our large compilation also allows us to report here the identification of 81 XBONG, 78 z>3 X-ray sources and 8 Type-2 QSO candidates. Also we have identified the highest redshift (z=5.4135) X-ray selected QSO with optical spectroscopy.Comment: 17 pages, 16 figures, accepted for publication in ApJS. Full data table and README file can be found online at http://hea-www.harvard.edu/~pgreen/Papers.htm

WormBase: a multi-species resource for nematode biology and genomics

WormBase (http://www.wormbase.org/) is the central data repository for information about Caenorhabditis elegans and related nematodes. As a model organism database, WormBase extends beyond the genomic sequence, integrating experimental results with extensively annotated views of the genome. The WormBase Consortium continues to expand the biological scope and utility of WormBase with the inclusion of large-scale genomic analyses, through active data and literature curation, through new analysis and visualization tools, and through refinement of the user interface. Over the past year, the nearly complete genomic sequence and comparative analyses of the closely related species Caenorhabditis briggsae have been integrated into WormBase, including gene predictions, ortholog assignments and a new synteny viewer to display the relationships between the two species. Extensive site-wide refinement of the user interface now provides quick access to the most frequently accessed resources and a consistent browsing experience across the site. Unified single-page views now provide complete summaries of commonly accessed entries like genes. These advances continue to increase the utility of WormBase for C.elegans researchers, as well as for those researchers exploring problems in functional and comparative genomics in the context of a powerful genetic system

Parietal white matter lesions in Alzheimer’s disease are associated with cortical neurodegenerative pathology, but not with small vessel disease

The research was supported by the Alzheimer’s Society (Grant Number: AS-PG-2013-011). Tissue for this study was provided by the Newcastle Brain Tissue Resource, which is funded in part by a grant from the UK Medical Research Council (G0400074) and by Brains for Dementia research, a joint venture between Alzheimer’s Society and Alzheimer’s Research UK.Cerebral white matter lesions (WML) encompass axonal loss and demyelination, and the pathogenesis is assumed to be small vessel disease (SVD)-related ischemia. However, WML may also result from the activation of Wallerian degeneration as a consequence of cortical Alzheimer’s disease (AD) pathology, i.e. hyperphosphorylated tau (HPτ) and amyloid-beta (Aβ) deposition. WML seen in AD have a posterior predominance compared to non-demented individuals but it is unclear whether the pathological and molecular signatures of WML differ between these two groups. We investigated differences in the composition and aetiology of parietal WML from AD and non-demented controls. Parietal WML tissue from 55 human post-mortem brains (AD, n = 27; non-demented controls, n = 28) were quantitatively assessed for axonal loss and demyelination, as well as for cortical HPτ and Aβ burden and SVD. Biochemical assessment included Wallerian degeneration protease calpain and the myelin-associated glycoprotein (MAG) to proteolipid protein (PLP) ratio (MAG:PLP) as a measure of hypoperfusion. WML severity was associated with both axonal loss and demyelination in AD, but only with demyelination in controls. Calpain was significantly increased in WML tissue in AD, whereas MAG:PLP was significantly reduced in controls. Calpain levels were associated with increasing amounts of cortical AD-pathology but not SVD. We conclude that parietal WML seen in AD differ in their pathological composition and aetiology compared to WML seen in aged controls: WML seen in AD may be associated with Wallerian degeneration that is triggered by cortical AD-pathology, whereas WML in aged controls are due to ischaemia. Hence, parietal WML as seen on MRI should not invariably be interpreted as a surrogate biomarker for SVD as they may be indicative of cortical AD-pathology, and therefore, AD should also be considered as the main underlying cause for cognitive impairment in cases with parietal WML.Publisher PDFPeer reviewe

Correction: Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations.

The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment of therapeutic benefit in clinical trials often relies on tools developed for other conditions, such as Alzheimer's or Parkinson's disease. These may not be sufficiently valid or sensitive to treatment changes in DLB, decreasing their utility. In this review, we discuss the limitations and strengths of selected available tools used to measure DLB-associated outcomes in clinical trials and highlight the potential roles for more specific objective measures. We emphasize that the existing outcome measures require validation in the DLB population and that DLB-specific outcomes need to be developed. Finally, we highlight how the selection of outcome measures may vary between symptomatic and disease-modifying therapy trials

Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations

The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment of therapeutic benefit in clinical trials often relies on tools developed for other conditions, such as Alzheimer's or Parkinson's disease. These may not be sufficiently valid or sensitive to treatment changes in DLB, decreasing their utility. In this review, we discuss the limitations and strengths of selected available tools used to measure DLB-associated outcomes in clinical trials and highlight the potential roles for more specific objective measures. We emphasize that the existing outcome measures require validation in the DLB population and that DLB-specific outcomes need to be developed. Finally, we highlight how the selection of outcome measures may vary between symptomatic and disease-modifying therapy trials

Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations.

The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment of therapeutic benefit in clinical trials often relies on tools developed for other conditions, such as Alzheimer's or Parkinson's disease. These may not be sufficiently valid or sensitive to treatment changes in DLB, decreasing their utility. In this review, we discuss the limitations and strengths of selected available tools used to measure DLB-associated outcomes in clinical trials and highlight the potential roles for more specific objective measures. We emphasize that the existing outcome measures require validation in the DLB population and that DLB-specific outcomes need to be developed. Finally, we highlight how the selection of outcome measures may vary between symptomatic and disease-modifying therapy trials